Pamela Foulds
Chief Tech/Sci/R&D Officer at FREELINE THERAPEUTICS HOLDINGS PLC
Network origin in Pamela Foulds first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Biotechnology | 21 | |
Auregen Biotherapeutics SA
 Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland.
8
| Holding Company | Packaged Software | 8 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Pamela Foulds via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder Director/Board Member Founder Director/Board Member Human Resources Officer | |
Commave Therapeutics SA
 Commave Therapeutics SA Pharmaceuticals: MajorHealth Technology Commave Therapeutics SA is a Swiss pharmaceutical manufacturing company. The private company is based in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Auregen Biotherapeutics, Inc.
 Auregen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auregen Biotherapeutics, Inc. provides biotechnology services. The CEO of the American company is Richard John Davies. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Administrative Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| BECTON, DICKINSON AND COMPANY | Medical Specialties | Corporate Officer/Principal | |
| ABEONA THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Biotechnology | Founder | |
| Royal Free Hospital Medical School | College/University | Corporate Officer/Principal | |
| University College London | College/University | Corporate Officer/Principal | |
| University of Aberdeen | College/University | Undergraduate Degree | |
| The Open University | College/University | Doctorate Degree | |
Akin, Gump, Strauss, Hauer & Feld LLP
 Akin, Gump, Strauss, Hauer & Feld LLP Miscellaneous Commercial ServicesCommercial Services Akin Gump Strauss Hauer & Feld LLP provides legal services. The firm's areas of practice includes appellate, litigation, business and commercial litigation, dispute resolution, government contracts, internal investigations, labor and employment, oil and gas patent, trademark and copyright infringement, product liability and toxic tort securities litigation. The company was founded in 1971 and is headquartered in Washington, DC. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
The District of Columbia Bar
 The District of Columbia Bar Miscellaneous Commercial ServicesCommercial Services The District of Columbia Bar provides legal services. The private company is based in Washington. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
New York State Bar Association
 New York State Bar Association Miscellaneous Commercial ServicesCommercial Services New York State Bar Association is a non-profit organization, which provides legal services and offers a membership program for lawyers. It also publishes an array of books, bar journals, law digest, and State Bar news. The company was founded in 1876 and is headquartered in Alban, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| LEXICON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Georgetown University Law Center | College/University | Graduate Degree | |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Pharmaceuticals: Major | Director/Board Member | |
| PRAXIS PRECISION MEDICINES, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ADICET BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
| SCHRÖDINGER, INC. | Packaged Software | Director/Board Member | |
Veterans Administration Medical Center
 Veterans Administration Medical Center Hospital/Nursing ManagementHealth Services Veterans Administration Medical Center provides healthcare services. The private company is based in San Diego, CA. | Hospital/Nursing Management | Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
The American Society for Clinical Pharmacology & Therapeutics
 The American Society for Clinical Pharmacology & Therapeutics Miscellaneous Commercial ServicesCommercial Services The American Society for Clinical Pharmacology & Therapeutics is a scientific and professional organization that serves the disciplines of clinical pharmacology and translational medicine. The non-profit company is based in Alexandria, VA. The CEO of the company is Sharon Swan. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Infectious Diseases Society of America
 Infectious Diseases Society of America Miscellaneous Commercial ServicesCommercial Services The Infectious Diseases Society of America is a non-profit company that provides clinical practice guidelines development and guideline panelists for infectious diseases. The company is based in Arlington, VA and has subsidiaries in the United States. The company specializes in antimicrobial stewardship and have established Antimicrobial Stewardship Centers of Excellence. The CEO of the company is Christopher Busky. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Yale School of Medicine | College/University | Doctorate Degree | |
| Yale University | College/University | Undergraduate Degree | |
| TETRAPHASE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Immodulon Therapeutics Ltd.
 Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Biotechnology | Chairman | |
| Georgetown University | College/University | Undergraduate Degree | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Marshall University | College/University | Undergraduate Degree | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Meredith College | College/University | Masters Business Admin | |
| Boston College | College/University | Undergraduate Degree | |
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC is a joint venture company that focuses on discovering, developing, and commercializing gene-editing therapeutics to treat genetic causes of bleeding disorders and autoimmune diseases. The company is based in Cambridge, MA. | Pharmaceuticals: Generic | Corporate Officer/Principal | |
Exo Therapeutics, Inc.
 Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director of Finance/CFO | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Technical University of Denmark | College/University | Masters Business Admin | |
| University of Copenhagen | College/University | Graduate Degree | |
| TAYSHA GENE THERAPIES, INC. | Biotechnology | Director/Board Member | |
| George Mason University | College/University | Doctorate Degree | |
| University of the Witwatersrand | College/University | Doctorate Degree | |
| KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Loughborough University | College/University | Undergraduate Degree | |
| New York University | College/University | Undergraduate Degree | |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
| William & Mary School of Law | College/University | Graduate Degree |
Statistics
International
| United States | 36 |
| United Kingdom | 11 |
| Denmark | 4 |
| Switzerland | 2 |
| South Africa | 2 |
Sectoral
| Health Technology | 25 |
| Consumer Services | 19 |
| Commercial Services | 7 |
| Technology Services | 2 |
| Health Services | 2 |
Operational
| Director/Board Member | 63 |
| Corporate Officer/Principal | 35 |
| Independent Dir/Board Member | 19 |
| Chairman | 15 |
| Undergraduate Degree | 13 |
Most connected contacts
| Insiders | |
|---|---|
| Julia Gregory | 22 |
| Chris Hollowood | 19 |
| Richard Davies | 15 |
| Jeffrey Chodakewitz | 15 |
| Colin Love | 11 |
| Eric Fink | 8 |
| Michael Parini | 8 |
| Giampiero de Luca | 7 |
| Martin Andrews | 7 |
| Amit Chunilal Nathwani | 7 |
| Stephen P. Diamond | 5 |
| Alison Long | 5 |
| James Bircher | 4 |
| Paul Schneider | 4 |
| Henning R. Stennicke | 4 |
- Stock Market
- Insiders
- Pamela Foulds
- Company connections
